Module 4 - Disorders of Excessive Sleepiness Flashcards

1
Q

What is narcolepsy?

A

A disorder of sleep-wake instability. It involves fragmented sleep during the night and unwanted, excessive sleep during the day. It may also include REM sleep intruding into wakefulness.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What causes narcolepsy?

A

The exact cause is unknown. There is likely a genetic component. Rare secondary causes include head injury, tumours, infections, or autoimmune attack.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the role of orexin/hypocretin?

A

Orexin (aka hypocretin) is a neuropeptide that regulates arousal, wakefulness, and REM sleep suppression. In Narcolepsy Type 1, orexin is absent or very low.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is cataplexy?

A

Sudden, often emotionally triggered loss of muscle tone while awake, due to REM atonia intruding into wakefulness. Consciousness is preserved.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the two main types of narcolepsy?

A

• Narcolepsy Type 1 (NT1): Excessive daytime sleepiness, Cataplexy, Low or absent orexin in CSF.
• Narcolepsy Type 2 (NT2): Excessive daytime sleepiness, No cataplexy, Normal orexin levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the prevalence of narcolepsy with cataplexy (NT1)?

A

About 0.03–0.06% in the general population.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the typical onset age of narcolepsy?

A

10–25 years (primary peak), with a second smaller peak at 35–45 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How does narcolepsy differ in children?

A

Children often show: • Longer sleep periods • Less REM-related symptoms • Rapid weight gain • Complex cataplexy (e.g., facial slackening, unsteady gait)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the classic tetrad of narcolepsy symptoms?

A
  1. Excessive Daytime Sleepiness (EDS) – 100% of cases 2. Cataplexy 3. Sleep paralysis 4. Hypnagogic/hypnopompic hallucinations.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the EDS seen in narcolepsy.

A

• Daily and severe • Irresistible sleep episodes, often brief and refreshing • Triggered by inactivity (e.g., driving, lectures) • Causes inattention, poor memory, reduced QoL • Episodes often include dreaming.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does EDS in narcolepsy differ from idiopathic hypersomnia?

A

Narcoleptic naps are brief and refreshing; idiopathic hypersomnia naps are long and unrefreshing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What triggers cataplexy?

A

Strong emotions like laughter, surprise, anger, elation, anticipation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Is awareness preserved during cataplexy?

A

Yes. Patients remain conscious and aware.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the different forms of cataplexy?

A

• Partial cataplexy: Most common; jaw slackening, head drop, speech slurring • Full cataplexy: Sudden collapse affecting all voluntary muscles • Status cataplecticus: Rare prolonged form; can occur with medication withdrawal.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How does cataplexy appear in children?

A

Often presents as: • Generalised hypotonia • Slack jaw, tongue protrusion, unsteady gait • Dyskinetic-like movements. These usually evolve into classic cataplexy over time.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is sleep paralysis?

A

A REM-related symptom where a person feels awake but unable to move or speak, typically occurring at sleep onset or awakening.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Is sleep paralysis unique to narcolepsy?

A

No. It occurs in ~7.6% of the general population as an isolated symptom.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are hypnagogic and hypnopompic hallucinations?

A

Vivid, dream-like hallucinations at sleep onset (hypnagogic) or upon waking (hypnopompic), often visual or auditory.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How can these hallucinations be misdiagnosed?

A

They may be mistaken for psychosis due to their vivid and disturbing nature.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What dream-related phenomena are common in narcolepsy?

A

• Vivid and lucid dreams • Nightmares • Dream delusions (false memories from vivid dreams).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How is nocturnal sleep affected in narcolepsy?

A

Fragmented sleep, increased light sleep, frequent awakenings, and higher rates of REM behaviour disorder and periodic limb movements (PLMs).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the primary neurochemical abnormality in Narcolepsy Type 1?

A

Loss of orexin/hypocretin-producing neurons in the lateral hypothalamus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How do orexin neurons normally function?

A

They are active during wakefulness and suppressed during sleep. They stabilise transitions between sleep and wake states.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What happens when orexin is absent or reduced?

A

Individuals cannot maintain stable sleep-wake states. REM sleep intrudes into wakefulness (e.g., cataplexy), and fragmented sleep occurs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What HLA allele is strongly associated with NT1?

A

HLA DQB1*0602 — present in nearly all NT1 patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Is HLA typing diagnostic for narcolepsy?

A

No — it’s associated but not diagnostic. Up to 45% of NT2 patients also carry it.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is the likely mechanism of hypocretin neuron destruction in NT1?

A

Autoimmune attack, possibly involving T-cell cross-reactivity with influenza antigens (molecular mimicry).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What evidence supports an autoimmune basis for NT1?

A

• Presence of CD4⁺ and CD8⁺ T-cells targeting hypocretin peptides • Association with HLA alleles • Pandemrix (H1N1 vaccine) spike in NT1 cases • Post-mortem findings show hypocretin neuron loss.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What neurotransmitters are implicated in narcolepsy beyond hypocretin?

A

• Cholinergic system: Regulates REM sleep; may be defective in narcolepsy • Monoamines (noradrenaline, serotonin): Modulate REM via cholinergic inhibition.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What are orexin’s broader roles in the CNS?

A

Beyond sleep-wake regulation, orexin influences: • Appetite • Body temperature • Blood pressure • Reward pathways.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What has post-mortem research shown in narcoleptic patients?

A

• Undetectable levels of pre-prohypocretin RNA • Loss of hypocretin-producing neurons in the hypothalamus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What rare genetic finding has been identified in narcolepsy?

A

A mutation in the hypocretin gene was reported in one patient.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What is the link between narcolepsy and influenza vaccination?

A

In 2009–2010, children/adolescents in Europe developed NT1 soon after receiving the Pandemrix H1N1 vaccine, suggesting a vaccine-triggered autoimmune response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Does narcolepsy present later in life?

A

Rarely, but there’s a smaller peak in onset around 35–45 years, and some cases even occur in older adults (e.g., cataplexy as first symptom post-60).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What are the two core diagnostic pathways for Narcolepsy Type 1 (NT1)?

A
  1. Clinical history of EDS and cataplexy + MSLT showing: • Mean sleep latency ≤ 8 minutes • ≥ 2 SOREMPs 2. Low CSF hypocretin-1 level (≤110 pg/mL).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What is required to diagnose Narcolepsy Type 2 (NT2)?

A

• EDS + MSLT showing: • Mean sleep latency ≤ 8 minutes • ≥ 2 SOREMPs • Normal orexin levels • No cataplexy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What is the role of PSG in diagnosing narcolepsy?

A

• Rule out other causes of EDS (e.g., OSA, periodic limb movements) • Evaluate sleep efficiency and architecture • Detect nocturnal SOREMPs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What PSG findings are typical in narcolepsy?

A

• Low sleep efficiency (≤85%) • Fragmented sleep • 40% have significant PLMs • No significant AHI (if OSA ruled out).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What does the MSLT assess?

A

Sleep propensity — how quickly someone falls asleep during 5 nap opportunities across the day.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

How is the MSLT conducted?

A

• Five 20-minute nap trials, spaced every 2 hours • Performed the day after a PSG • Monitors time to sleep onset and occurrence of REM.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What are the diagnostic criteria on MSLT for narcolepsy?

A

• Mean sleep latency ≤ 8 minutes • ≥2 SOREMPs (REM within 15 mins of sleep onset).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

When can MSLT give false positives?

A

• Sleep restriction • Untreated OSA • Medication effects (esp. withdrawal from REM-suppressing drugs) • Shift workers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

When is CSF hypocretin testing used?

A

• When MSLT is not possible or unreliable • In patients on multiple medications • In children or individuals with unusual symptoms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What CSF hypocretin level supports NT1 diagnosis?

A

≤110 pg/mL (which is ≤1/3 of normal levels).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What is the function of hypocretin?

A

Maintains wakefulness and regulates REM sleep.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

What HLA markers are associated with NT1?

A

HLA DR2 and more specifically DQB1*0602.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Is HLA typing diagnostic?

A

No — it supports the diagnosis but lacks specificity. 45% of NT2 patients may also carry the allele.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

What should raise suspicion of narcolepsy in young patients?

A

Severe daytime sleepiness, especially if unresponsive to improved sleep hygiene and not explained by other conditions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

What might mislead diagnosis based on SOREMPs alone?

A

Night/shift work and certain medications can produce false positives.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

How do Narcolepsy Type 1 and Type 2 differ in terms of orexin levels and clinical features?

A

• Type 1 (NT1): Characterised by low or absent orexin levels, presence of cataplexy, and ≥2 SOREMPs on MSLT. • Type 2 (NT2): Orexin levels are normal, cataplexy is absent, and ≥2 SOREMPs may be present, though some cases later evolve into NT1. • Both types have mean sleep latency ≤8 minutes, but only NT1 is consistently linked with the HLA DQB1*0602 allele.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

What are the differences between MSLT, PSG, and CSF hypocretin testing in diagnosing narcolepsy?

A

• MSLT (Multiple Sleep Latency Test) measures how quickly a person falls asleep and whether they enter REM quickly during the day. It’s the gold-standard objective measure for diagnosing EDS and REM intrusion. • PSG (Polysomnography) is an overnight sleep study used to rule out other sleep disorders like OSA and assess sleep architecture; it’s always performed the night before an MSLT. • CSF Hypocretin Testing involves a lumbar puncture to measure orexin levels. It is diagnostic for NT1 if levels are ≤110 pg/mL and is used when MSLT results are inconclusive or can’t be obtained.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What are the main medication classes used to treat narcolepsy?

A
  1. Wake-promoting agents (e.g., modafinil)
  2. Stimulants (e.g., amphetamines, methylphenidate)
  3. Sodium oxybate
  4. Antidepressants (for cataplexy)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

What is modafinil and how is it used in narcolepsy?

A

A wakefulness-promoting agent

First-line treatment for EDS in narcolepsy (PBS-listed in Australia)

Typical dose: 200–400 mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

What are the benefits of modafinil over amphetamines?

A
  • Lower abuse potential
  • No rebound hypersomnolence
  • Longer half-life with R-modafinil (9–14 hrs)
  • Fewer psychiatric side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

What are the side effects and interactions of modafinil?

A
  • Headache, nausea, nervousness
  • Induces CYP450 → may reduce effectiveness of oral contraceptives
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

When are stimulants used in narcolepsy?

A
  • Typically second-line, especially for severe EDS
  • May be more effective than modafinil but with higher side effect risk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

How do stimulants work?

A

Block reuptake of dopamine and other monoamines → increase arousal and alertness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Common side effects of stimulants?

A

Nervousness, irritability, headaches, palpitations, anorexia, insomnia, psychosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

What are concerns with stimulant use?

A
  • Abuse potential (though rare)
  • Tolerance and rebound effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

What is sodium oxybate and how is it used?

A
  • The sodium salt of gamma-hydroxybutyrate (GHB)
  • Used to treat cataplexy and improve nighttime sleep
  • Can also reduce EDS at higher doses
  • Dose: 4.5–9 g nightly in 2 doses (due to short half-life)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

What are the benefits of sodium oxybate?

A
  • Reduces cataplexy
  • Improves nocturnal sleep (↑ SWS and REM)
  • May improve daytime alertness at higher doses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

What are the side effects and limitations of sodium oxybate?

A
  • Dizziness, headaches, transient amnesia
  • Abuse potential (is a known ‘date rape’ drug)
  • Requires strict dosing and has high cost
  • TGA-approved but not PBS-listed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Which antidepressants may be used to manage cataplexy?

A

SSRIs, SNRIs, and TCAs can suppress REM sleep and reduce cataplexy frequency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Why are antidepressants used in narcolepsy?

A

REM suppression helps reduce cataplexy, sleep paralysis, and hypnagogic hallucinations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

What behavioural strategies are recommended for narcolepsy management?

A
  • Maintain consistent sleep-wake schedule
  • Avoid shift work
  • Practise good sleep hygiene
  • Schedule short daytime naps (~15–30 min)
  • Use caffeine strategically (avoid late in day)
  • Avoid prolonged inactivity
  • Incorporate daytime physical activity
  • Manage stress
  • Optimise weight (due to obesity risk)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

What lifestyle modifications and supports are important in narcolepsy?

A
  • Driving restrictions and fitness-to-drive assessment
  • Workplace and school accommodations (e.g., nap breaks, flexible schedules)
  • Regular follow-up to monitor symptoms and adjust treatment
  • Patient education about the chronic nature of the condition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Which treatments target EDS vs. cataplexy?

A
  • EDS: Modafinil, amphetamines, sodium oxybate (high dose)
  • Cataplexy: Sodium oxybate (low dose), antidepressants
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

What is idiopathic hypersomnia (IH)?

A

A central disorder of hypersomnolence characterised by excessive daytime sleepiness despite adequate or prolonged nighttime sleep, without another identifiable cause (e.g., narcolepsy, OSA).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

What are the hallmark symptoms of IH?

A
  • Severe, constant daytime sleepiness
  • Prolonged, unrefreshing naps
  • Difficulty waking (sleep inertia or “sleep drunkenness”)
  • Sleep duration often >10 hours in 24 hours
  • Long and deep nocturnal sleep
  • Autonomic dysfunction in some (headaches, temperature dysregulation, orthostatic issues)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

How do naps in IH differ from those in narcolepsy?

A

IH naps are long and unrefreshing, while narcoleptic naps are short and restorative.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

What is the prevalence of IH?

A

Seen in 1–10% of patients presenting to sleep clinics for EDS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

How is IH diagnosed?

A
  • Clinical history of EDS
  • PSG showing high sleep efficiency and long TST (>660 mins)
  • MSLT with mean sleep latency ≤8 mins and 0–1 SOREMPs
  • Rule out other causes: OSA, narcolepsy, psychiatric disorders, medications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

What are the PSG findings in IH?

A
  • Normal architecture
  • Decreased latency to sleep
  • TST >660 mins
  • High sleep efficiency (>90%)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

What are the MSLT findings in IH?

A
  • Mean sleep latency ≤8 mins
  • Fewer than 2 SOREMPs

(SOREMPs are a key differentiator from narcolepsy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

What are the key differences between IH and Narcolepsy Type 1/2?

A

Cataplexy: Present only in NT1

  • Orexin: Low in NT1; normal in IH
  • SOREMPs: ≥2 in narcolepsy; 0–1 in IH
  • Sleep duration: Often prolonged in IH (>10 hrs)
  • Naps: Refreshing in narcolepsy; unrefreshing in IH
  • REM Intrusions: Common in narcolepsy (hallucinations, sleep paralysis); rare in IH
  • Hypocretin testing: Abnormal only in NT1
  • Dream delusions: More common in narcolepsy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

What comorbid conditions are common in IH?

A
  • Autonomic symptoms (Raynaud’s, temperature dysregulation)
  • Headaches
  • Potential viral onset in some cases
  • Psychiatric symptoms like depression and anxiety (as in narcolepsy)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Can IH resolve spontaneously?

A

Yes — spontaneous remission is reported in up to 14% of cases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Is histamine implicated in IH?

A

Possibly — low CSF histamine levels have been reported, but findings remain controversial.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

What psychiatric comorbidities are common in narcolepsy?

A
  • Depression
  • Anxiety
  • Obsessive-compulsive disorder
  • Rarely: psychosis
  • ADHD-like symptoms (especially in children and adolescents)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Are ADHD symptoms in narcolepsy purely due to sleepiness?

A

No — even after treating EDS, many patients show persistent executive dysfunction, suggesting intrinsic neurocognitive deficits.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

What sleep-related comorbidities are common in narcolepsy?

A
  • REM Sleep Behaviour Disorder (20–60%)
  • Periodic Limb Movements of Sleep (PLMS) – ≥15/hour in 10%
  • Disrupted nocturnal sleep with frequent awakenings
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

What autonomic dysfunctions are reported in NT1?

A
  • Blunted heart rate response to arousals
  • Lack of normal nocturnal BP dip (nondipping pattern)
  • Possible contribution to metabolic issues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

How does narcolepsy affect day-to-day functioning?

A
  • Impaired academic and occupational performance
  • Memory lapses and inattention
  • Frequent, unwanted sleep episodes
  • Emotional distress due to cataplexy and hallucinations
  • Social withdrawal due to unpredictability of symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

How can narcolepsy affect driving and employment?

A
  • Increased risk of motor vehicle accidents (MVA)
  • Driving restrictions may be required
  • Job dismissal, early retirement, and work disability are more common
  • Sleepiness during work hours affects productivity and safety
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

What was the result of the large US study on narcolepsy burden (n=55,871)?

A
  • Higher healthcare utilisation and medical costs
  • Increased rates of disability leave
  • Greater personal and economic impact than matched controls
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

What school or workplace accommodations might patients with narcolepsy need?

A
  • Scheduled nap breaks
  • Flexibility with start/end times
  • Movement breaks
  • Avoiding prolonged sedentary tasks
  • Time allowances for memory/attention lapses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

Why is narcolepsy often underdiagnosed or misdiagnosed?

A
  • EDS is a nonspecific symptom often attributed to lifestyle
  • Symptoms like hallucinations and paralysis may be mistaken for psychiatric illness
  • Cataplexy may be overlooked if partial or mistaken for clumsiness
  • Lack of awareness among general practitioners
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

What symptom is unique to narcolepsy and helps distinguish it from other conditions?

A

Cataplexy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

How is sleepiness defined physiologically?

A

Sleepiness is a multicausal physiological need state, not simply a symptom. It represents a drive to sleep and is influenced by homeostatic, circadian, and neurobiological factors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

How did the scientific view of sleepiness evolve?

A

In the 1960s, EDS began to be recognised as a legitimate, measurable, and medically important symptom — not just laziness or narcolepsy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

What are the main determinants of sleepiness?

A
  1. Quantity and quality of prior sleep
  2. Circadian phase
  3. Central nervous system disorders or dysfunction
  4. Sleep fragmentation or interruption
  5. Neurochemical signalling (e.g., adenosine, GABA, dopamine, orexin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

What brain regions are involved in sleep-wake regulation and alertness?

A
  • Ascending reticular activating system (ARAS)
  • Hypothalamus (lateral and ventrolateral preoptic areas)
  • Basal forebrain
  • Thalamus
  • Brainstem nuclei
  • Cerebral cortex (for subjective perception and responsiveness)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

What role does the hypothalamus play in sleepiness?

A

It integrates circadian and homeostatic signals and regulates transitions between sleep and wake via orexin and VLPO-mediated GABA release.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

Which neurotransmitters promote wakefulness?

A
  • Dopamine
  • Noradrenaline
  • Histamine
  • Acetylcholine
  • Orexin (hypocretin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

Which neurotransmitters promote sleep or suppress wakefulness?

A
  • GABA
  • Adenosine
  • Serotonin (in some contexts)
  • Melatonin (circadian signal)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

What is the role of adenosine in sleepiness?

A

Adenosine accumulates during wakefulness and promotes sleep drive by inhibiting wake-active neurons. Caffeine promotes alertness by blocking adenosine receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

What is the function of orexin in regulating alertness?

A

Orexin stabilises wakefulness by activating wake-promoting systems. Its absence leads to narcolepsy with REM intrusion (NT1).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

How do homeostatic and circadian processes interact to regulate sleepiness?

A
  • Homeostatic sleep drive increases the longer you’re awake.
  • Circadian rhythms modulate alertness independent of sleep need, with dips (e.g., early afternoon) and peaks (late morning, early evening).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

When is sleepiness most likely to occur based on circadian phase?

A
  • Early morning (e.g., ~3–6 a.m.)
  • Early afternoon (post-lunch dip)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
100
Q

Can monotony cause sleepiness?

A

No — it can unmask latent sleepiness but is not a cause. True physiological sleepiness results from underlying biological processes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
101
Q

What is the most widely used subjective scale for measuring sleepiness?

A

The Epworth Sleepiness Scale (ESS)

102
Q

What does the Epworth Sleepiness Scale assess?

A

A person’s likelihood of dozing in eight routine daytime situations (e.g., watching TV, sitting in traffic), rated 0–3 for each; total score 0–24.

103
Q

What ESS score indicates clinically significant sleepiness?

A
  • >10 is considered abnormally sleepy
  • >15 suggests severe EDS
104
Q

What does the MSLT measure?

A
  • Mean sleep latency (how quickly one falls asleep)
  • Number of SOREMPs (sleep-onset REM periods)
105
Q

How is the MSLT conducted?

A
  • 5 nap opportunities, 2 hours apart
  • Each nap lasts 20 minutes unless sleep occurs
  • Performed after a full overnight PSG to rule out other causes
106
Q

What MSLT results indicate abnormal sleepiness?

A
  • Mean sleep latency ≤8 minutes
  • ≥2 SOREMPs suggests narcolepsy
  • 0–1 SOREMPs with short latency suggests IH
107
Q

Limitations of MSLT?

A
  • Doesn’t reflect real-world functioning
  • Can produce false positives (e.g., sleep restriction, medication withdrawal)
  • Doesn’t assess ability to resist sleep
108
Q

What does the MWT measure?

A

Ability to stay awake in a quiet, non-stimulating environment — i.e., behavioural alertness.

109
Q

How is the MWT different from MSLT?

A
  • MWT assesses resistance to sleep, not sleep propensity
  • Better suited to assessing real-world safety (e.g., fitness to drive)
110
Q

When is the MWT used clinically?

A
  • Assessing treatment response (e.g., to modafinil)
  • Legal/occupational evaluations (e.g., pilots, drivers)
  • Determining fitness to drive
111
Q

What MWT result indicates normal wakefulness?

A

Ability to stay awake for ≥40 minutes on 4 trials is generally considered normal.

112
Q

What are some emerging or alternative ways of assessing sleepiness?

A
  • Psychomotor vigilance testing (PVT): reaction time to visual stimuli
  • EEG and pupillometry: physiological correlates of alertness
  • Actigraphy + subjective scales: used in field settings
113
Q

Why is sleepiness assessment important beyond diagnosis?

A

To monitor treatment response, assess functional capacity, and ensure safety (e.g., driving).

114
Q

Why is excessive daytime sleepiness (EDS) considered a public health issue?

A
  • It impairs performance, alertness, and reaction time
  • Increases risk of accidents (esp. driving & workplace injuries)
  • Reduces quality of life and functional capacity
  • Carries significant economic costs (e.g., absenteeism, healthcare usage)
115
Q

What real-world domains are most affected by sleepiness?

A
  • Occupational performance
  • Driving and transport safety
  • Academic performance
  • Cognitive function (attention, memory, decision-making)
  • Social and emotional functioning
116
Q

How does EDS impact psychosocial wellbeing?

A
  • Contributes to low mood, irritability, and frustration
  • Can lead to social withdrawal and relationship strain
  • Associated with psychiatric conditions like depression and anxiety
117
Q

What are the occupational consequences of untreated sleepiness?

A
  • Reduced productivity and efficiency
  • Increased errors and risk of injury
  • Absenteeism and presenteeism
  • Higher rates of disability claims and job loss
118
Q

How does sleepiness compare to alcohol in terms of impairment?

A

Being awake for 18–24 hours can impair driving performance to a degree equivalent to a BAC of 0.05–0.10%.

119
Q

What professions are at higher risk due to sleepiness?

A
  • Shift workers
  • Healthcare professionals
  • Transport operators (pilots, truck drivers)
  • Machine operators
  • Students (due to sleep restriction and irregular schedules)
120
Q

What cognitive functions are impaired by sleepiness?

A
  • Attention and vigilance
  • Working memory
  • Executive function and decision-making
  • Reaction time
121
Q

Q: Does sleepiness impair performance uniformly across tasks?

A

No — monotonous, low-stimulation tasks (e.g., driving, surveillance) are affected the most.

122
Q

What are the chronic effects of long-term EDS if untreated?

A
  • Increased risk of depression and anxiety
  • Diminished QoL and wellbeing
  • Strained interpersonal relationships
  • Occupational instability
  • Higher healthcare use and medical costs
123
Q

What population-wide strategies can reduce the burden of sleepiness?

A
  • Public education about sleep hygiene and circadian health
  • Screening and treatment of sleep disorders
  • Workplace fatigue management programs
  • Regulation of shift work and transport industry safety
124
Q

What is the difference between sleepiness and fatigue?

A
  • Sleepiness: A physiological drive to sleep; involves the tendency to fall asleep
  • Fatigue: A subjective lack of energy or mental/physical exhaustion without necessarily feeling sleepy
125
Q

How do patients describe fatigue vs. sleepiness?

A
  • Fatigue: “Drained”, “exhausted”, “burned out”
  • Sleepiness: “Can’t keep my eyes open”, “nodding off”, “dozing during the day”
126
Q

Why is it clinically important to differentiate sleepiness from fatigue?

A
  • They have different causes and treatment pathways
  • Fatigue may stem from anaemia, depression, chronic illness, or deconditioning
  • Sleepiness points more toward sleep disorders or circadian misalignment
127
Q

What can help clarify the distinction during clinical history taking?

A
  • Ask about dozing off vs. feeling tired
  • Inquire about refreshment after naps (usually not seen in fatigue)
  • Use validated scales like ESS (sleepiness) or fatigue-specific questionnaires
128
Q

What should a clinical assessment of EDS include?

A
  1. Detailed sleep history (duration, timing, quality)
  2. Work schedule and shift patterns
  3. Medication, substance use (incl. caffeine, alcohol, sedatives)
  4. Mood and psychiatric history
  5. Use of standardised tools (e.g., ESS, sleep diaries)
  6. Possible need for objective tests (MSLT, PSG)
129
Q

When should you refer a patient for objective testing (MSLT/PSG)?

A
  • When symptoms persist despite adequate sleep
  • If narcolepsy, idiopathic hypersomnia, or other central hypersomnolence is suspected
  • If EDS interferes with safety, work, or quality of life
130
Q

What are red flags that suggest true pathological sleepiness?

A
  • Sleep attacks during active situations
  • Involuntary dozing while driving, eating, or in conversation
  • History of vivid hallucinations or cataplexy-like symptoms
  • ESS score >15
131
Q

What are the three major contributors to excessive sleepiness?

A
  1. Sleep restriction or fragmentation
  2. Circadian misalignment
  3. Pathologic CNS conditions (e.g., narcolepsy)
132
Q

What makes sleepiness a distinct and measurable physiological state?

A
  • It involves identifiable neurochemical changes (e.g., adenosine, GABA, orexin)
  • It can be objectively measured (e.g., MSLT, MWT)
  • It has clear behavioural and performance correlates
133
Q

Why must sleepiness be taken seriously in clinical care?

A
  • It’s a symptom with significant safety, psychiatric, and functional consequences
  • Underlying causes are often treatable
  • Misdiagnosis (e.g., confusing with fatigue) delays intervention and support
134
Q

What sleep disorder is most commonly confused with IH?

A

Narcolepsy, particularly NT2 (without cataplexy) — due to overlapping symptoms like EDS and long naps .

135
Q

How can IH be differentiated from Narcolepsy Type 1 (NT1)?

A
  • NT1 usually has cataplexy, ≥2 SOREMPs, and low/absent CSF hypocretin-1
  • IH often shows long sleep times, sleep inertia, high sleep efficiency, and 0–1 SOREMPs
136
Q

What role does CSF hypocretin-1 play in distinguishing IH from narcolepsy?

A
  • Normal in 100% of IH patients
  • Low in NT1; may be low in NT2 if symptoms evolve
  • Low CSF hypocretin reclassifies patients to NT1 under ICSD-3
137
Q

What other conditions must be ruled out before diagnosing IH?

A
  • Sleep-disordered breathing (e.g., UARS)
  • Insufficient sleep syndrome
  • Medication effects
  • Depression/psychiatric disorders
  • Delayed sleep-wake phase disorder
  • Other neurologic/metabolic disorders
138
Q

What is Kleine-Levin Syndrome (KLS)?

A

A rare, relapsing-remitting disorder characterised by recurrent episodes of severe hypersomnia, cognitive dysfunction, derealisation, and behavioural changes

139
Q

What is the typical clinical presentation of KLS?

A
  • Mostly adolescent males
  • Sudden episodes of 18–20 hours sleep/day, lasting 1–3 weeks
  • Mutism, derealisation, disinhibited or childlike behaviour
  • Hyperphagia/hypersexuality in some
  • Complete recovery between episodes
140
Q

What are the diagnostic criteria for KLS?

A
  • ≥2 recurrent hypersomnia episodes (2 days–5 weeks)
  • Return to normal between episodes
  • At least one of: cognitive dysfunction, altered perception, eating disorder, disinhibited behaviour
  • Not better explained by other sleep/medical/psychiatric conditions
141
Q

How is KLS monitored?

A
  • Emergency sleep studies during episodes
  • 24–48hr EEG/PSG + behavioural observations
  • Report total sleep time, inappropriate behaviours, demeanour
142
Q

What is known about the cause of KLS?

A

Unclear — but autoimmune, genetic, and metabolic theories exist. Brain imaging often shows hypoperfusion in the parietotemporal and hypothalamic areas

143
Q

How common are sleep-wake disturbances after TBI?

A
  • 73% in subacute TBI
  • 52% in chronic TBI (2+ years post-injury)
  • Most common issues: EDS, hypersomnia, insomnia, fatigue
144
Q

What distinguishes sleep problems in subacute vs. chronic TBI?

A
  • Subacute: insomnia most common
  • Chronic: EDS and hypersomnia dominate
145
Q

What is posttraumatic hypersomnia?

A

The need for 2+ extra hours of sleep per day compared to baseline, not explained by another disorder

146
Q

Why are sleep-wake disturbances often missed in TBI patients?

A

TBI survivors often underestimate their sleep symptoms. Objective assessments (e.g., MSLT, actigraphy) are more reliable

147
Q

What causes posttraumatic sleep-wake disturbances?

A
  • Multifactorial: direct brain injury, secondary complications, circadian disruption, psychiatric comorbidities
  • Up to 43% have no identifiable cause, suggesting a primary neurologic basis
148
Q

What are long-term outcomes associated with sleep issues post-TBI?

A
  • Reduced rehabilitation outcomes
  • Increased psychiatric comorbidity
  • Persisting symptoms (e.g., fatigue, EDS) 3+ years post-injury
149
Q

Are circadian rhythm disturbances seen post-TBI?

A

Yes — includes delayed sleep phase and irregular sleep-wake rhythm; reduced melatonin output has been documented

150
Q

Is there a standard treatment protocol for KLS?

A

No. There is no established treatment, but some interventions show class IV evidence for benefit.

151
Q

What pharmacological treatments have shown some efficacy in KLS?

A
  • Lithium: May reduce episode frequency in patients with frequent episodes (>4/year)
  • IV corticosteroids: May reduce duration of prolonged episodes (>30 days)
  • Estrogen-progesterone: May help in menstrual-related KLS (limited data)
  • Antiepileptics & antidepressants: Not shown to be effective
152
Q

What is the general management approach during KLS episodes?

A
  • Allow the patient to sleep in a familiar home environment
  • Avoid hospitalisation unless necessary, to reduce anxiety
  • Educate families not to forcibly awaken or stimulate the patient
  • Prohibit driving during episodes due to altered perception and risk of accidents
  • Support and reassure families, document episodes via diaries or video
153
Q

What risks are associated with lithium therapy?

A
  • Thyroid and renal toxicity
  • Requires monitoring of serum lithium, TSH, and creatinine
  • May be tapered after several years of sustained benefit or after age 30
154
Q

What is the presumed cause of KLS?

A

Unknown, but evidence supports:

  • Autoimmune origin
  • Genetic predisposition
  • Possibly a localized recurrent encephalitis
155
Q

What brain areas are affected in KLS according to imaging studies?

A
  • Hypoperfusion in parietotemporal and mesiotemporal associative cortices
  • During episodes: ↓ activity in right dorsomedial prefrontal cortex and right parietotemporal junction
  • Some correlation with derealisation severity
156
Q

What histopathologic findings support a neuroinflammatory process in KLS?

A
  • Perivascular lymphocytes in hypothalamus, amygdala, thalamus, temporal lobes, midbrain
  • In some cases: reduced pigmentation in substantia nigra, smaller locus coeruleus
  • Supports theory of mild, localized encephalitis
157
Q

Is there evidence for autoimmune involvement in KLS?

A
  • Onset often follows infection, head trauma, or alcohol use
  • Partial benefit from IV steroids
  • No confirmed HLA associations or specific autoantibodies
  • Some cases may involve reversible CSF hypocretin-1 or histamine changes
158
Q

Are there known genetic risk factors for KLS?

A
  • Rare familial cases (~8%)
  • Variants in LMOD3 and TRANK1 genes have been found
  • No clear monogenic cause; likely polygenic susceptibility
159
Q

What must be ruled out before diagnosing KLS?

A
  • Acute confusional states in teenagers
  • Substance intoxication or withdrawal
  • Tumours (e.g., colloid cysts, craniopharyngiomas)
  • Encephalitis, seizures, autoimmune disease
  • Basilar migraine, porphyria, inborn errors of metabolism
  • Bipolar disorder, seasonal affective disorder, and other psychiatric illness
160
Q

What tests help exclude other causes in suspected KLS?

A
  • EEG (to exclude seizure activity; may show nonspecific slowing in KLS)
  • MRI or CT (to rule out mass lesions or stroke)
  • Blood tests: serum ammonia, B12, pyruvate, lactate
  • Consider spinal tap if febrile, to exclude CNS infection
  • Psychiatric assessment to rule out mood disorders
161
Q

How can KLS be differentiated from psychiatric disorders?

A
  • Episodes are stereotyped, abrupt, and followed by full recovery
  • Sleep duration and derealisation are much more pronounced in KLS
  • Brain imaging may show characteristic hypoperfusion patterns
  • Family and patient history (e.g., amnesia, altered speech, out-of-character behaviour) is key
162
Q

What are the proposed mechanisms of posttraumatic sleep-wake disturbance?

A
  • Direct injury to sleep-wake regulation centres (hypothalamus, brainstem)
  • Secondary effects (swelling, hypoxia, neuroinflammation, pain)
  • Disruption of neurotransmitter systems (e.g., orexin, dopamine, histamine)
  • Hypocretin neuron damage → possible transient narcolepsy phenotype
163
Q

What brain structures are commonly affected in TBI-related hypersomnia?

A

Hypothalamus, midbrain, and thalamus – especially areas involved in arousal and circadian regulation

164
Q

What is the general treatment approach to posttraumatic sleep-wake disorders?

A
  • Multidisciplinary: sleep specialists, neurologists, rehab
  • Treat comorbidities (pain, depression, insomnia)
  • Behavioural strategies: sleep hygiene, routine
  • Pharmacologic support (e.g., modafinil for EDS/hypersomnia, melatonin for circadian disruption)
165
Q

Is modafinil effective for posttraumatic hypersomnia or EDS?

A

May improve alertness, but evidence is limited and variable. Should be tailored to individual cases.

166
Q

What role does melatonin play post-TBI?

A

May help with circadian rhythm realignment, especially if melatonin secretion is impaired

167
Q

What conditions must be ruled out before diagnosing posttraumatic hypersomnia or EDS?

A
  • Obstructive sleep apnoea
  • Insufficient sleep syndrome
  • Depression or anxiety
  • Medication effects (sedatives, opioids)
  • Secondary narcolepsy (if cataplexy, hallucinations, SOREMPs present)
168
Q

What term has been proposed to describe prolonged sleep post-TBI without EDS?

A

Pleiosomnia – ≥2 hrs more sleep than pre-TBI baseline without subjective sleepiness

169
Q

Can TBI cause secondary narcolepsy?

A

Rarely. Typically lacks classic cataplexy, but may show SOREMPs and low hypocretin due to hypothalamic damage

170
Q

What circadian disorders are reported after TBI?

A
  • Delayed sleep-wake phase disorder
  • Irregular sleep-wake rhythm
  • Occurs in up to 36% of TBI patients with insomnia complaints
  • Often associated with blunted or delayed melatonin secretion
171
Q

How can circadian disorders be diagnosed post-TBI?

A
  • Actigraphy
  • Salivary melatonin rhythms
  • Core body temperature tracking
172
Q

What is the relationship between TBI and sleep misperception?

A

Patients frequently underestimate sleep duration and fail to report hypersomnia/EDS. Objective tools (e.g., actigraphy, MSLT) are essential

173
Q

What’s the impact of sleep-wake disorders on TBI recovery?

A
  • Poorer rehabilitation outcomes
  • Longer hospital stays
  • Worse cognitive performance, mood, and fatigue
  • Decreased quality of life and functional independence
174
Q

What comorbid symptoms exacerbate sleep issues post-TBI?

A

Pain, anxiety, PTSD, and depression — all worsen sleep and increase disability risk

175
Q

What are emerging biomarkers for sleepiness being researched?

A

These include:

  • Molecular markers (e.g., blood, urine, saliva proteins)
  • Genetic targets (e.g., gene expression post-wake)
  • Proteomic responses to homeostatic sleep pressure
  • Wearables capturing accelerometry and light exposure
  • PVT-based reaction time as a behavioural biomarker
    However, none are clinically validated yet
176
Q

What are dream delusions in narcolepsy?

A

Dream delusions are false memories formed from vivid or lucid dreams that are misinterpreted as real experiences. They’re more common in narcolepsy due to REM intrusion and dream realism, and may lead to confusion or mistaken beliefs about events.

177
Q

What role does the histaminergic system play in sleep-wake regulation?

A

Histamine is a CNS arousal-promoting neurotransmitter. Its activity helps maintain wakefulness, and low histaminergic tone may contribute to excessive sleepiness.

178
Q

What is the relevance of H3 antagonists in narcolepsy treatment?

A

H3 receptor antagonists/inverse agonists (e.g., pitolisant) increase histamine release by blocking presynaptic inhibition. They represent an emerging class of wake-promoting agents for narcolepsy and other hypersomnias, especially where stimulants are contraindicated.

179
Q

What is sleep inertia and how is it associated with idiopathic hypersomnia (IH)?

A

Sleep inertia refers to prolonged grogginess, disorientation, and cognitive sluggishness upon waking. It is a hallmark of IH and may last minutes to hours. Unlike narcolepsy, patients with IH often find waking extremely difficult and naps unrefreshing.

180
Q

How common is insomnia after TBI?

A

Prevalence varies widely (5–70%) due to differences in definitions and methods. It’s often over-reported subjectively and under-detected by PSG

181
Q

What contributes to insomnia after TBI?

A

Pain, anxiety, depression, dizziness, PTSD, and poor sleep hygiene.

182
Q

What are the functional consequences of post-TBI insomnia?

A

Worsened attention, headaches, fatigue, impaired rehab, increased disability risk.

183
Q

What parasomnias are seen after TBI?

A
  • Hypnagogic hallucinations (53%)
  • Sleep paralysis (15%)
  • REM sleep behaviour disorder (up to 9%)
  • Nightmares (up to 41%)
  • Nocturnal eating, sleepwalking, and enuresis in some patients

All suggest trauma to sleep-regulating brain circuits.

184
Q

How is dreaming affected post-TBI?

A
  • Decreased or absent dream recall early post-injury
  • Reduced vividness and frequency even during recovery
  • Increased nightmares later, which may worsen sleep fragmentation
185
Q

Which movement disorders may emerge post-TBI?

A
  • Bruxism (jaw clenching) – may contribute to post-traumatic headache
  • Restless Legs Syndrome (RLS) – appears pre-existing in most cases
  • PLMS – unclear if incidence increases; more common in spinal cord injury patients
186
Q

What are the key findings in paediatric TBI sleep research?

A
  • Few studies exist, but show persistent sleep disruption up to 2 years
  • Includes prolonged sleep onset, poor sleep maintenance, and reduced efficiency
  • Parental report often reveals issues even when children don’t self-report
  • Sleep problems worsen functional outcomes and learning
187
Q

What is the primary purpose of the Multiple Sleep Latency Test (MSLT)?

A

To objectively measure daytime sleepiness and support diagnoses such as narcolepsy or idiopathic hypersomnia.

188
Q

What two main outcomes does the MSLT report?

A
  1. Mean Sleep Latency (MSL)
  2. Number of Sleep Onset REM Periods (SOREMPs)
189
Q

What are the protocol requirements before conducting an MSLT?

A

• Nocturnal PSG with ≥6 hours sleep
• Sleep diary and/or actigraphy for 2 weeks
• Withdrawal of REM-affecting medications for 2+ weeks
• No caffeine or stimulants on test day
• Urine drug screen if needed

190
Q

How many naps are conducted during an MSLT and at what intervals?

A

Five nap opportunities are offered, spaced every 2 hours, beginning 1.5 to 3 hours after PSG wake-up.

191
Q

When is an MSLT nap trial terminated?

A
  1. After 20 minutes if no sleep occurs.
  2. If sleep occurs, continue monitoring for 15 minutes to detect REM sleep.
192
Q

Define a Sleep Onset REM Period (SOREMP).

A

REM sleep occurring within 15 minutes (clock time) after sleep onset.

193
Q

What is the diagnostic criteria for narcolepsy type 1 using MSLT/PSG?

A

MSL ≤ 8 minutes and ≥2 SOREMPs (can include PSG SOREMP) + cataplexy or low CSF hypocretin-1.

194
Q

What is the diagnostic criteria for narcolepsy type 2?

A

MSL ≤ 8 minutes and ≥2 SOREMPs without cataplexy. Other causes of sleepiness must be excluded.

195
Q

What are common causes of false-positive MSLT results?

A

• Shift work
• Circadian delay
• Recent REM-suppressant withdrawal
• Inadequate sleep
• Untreated OSA

196
Q

List the standard subjective measures of daytime sleepiness.

A

• Stanford Sleepiness Scale
• Epworth Sleepiness Scale (ESS)
• Karolinska Sleepiness Scale

197
Q

What is the difference between the MSLT and the MWT?

A

MSLT assesses ability to fall asleep; MWT assesses ability to stay awake in boring conditions.

198
Q

What is the standard procedure for a Maintenance of Wakefulness Test (MWT)?

A

Four 40-minute trials every 2 hours. Patient remains awake in a semi-upright position in a dimly lit room.

199
Q

What sleep onset criteria ends an MWT trial early?

A

Three epochs of stage 1 sleep or one epoch of any other stage ends the trial before 40 minutes.

200
Q

What factors influence mean sleep latency (MSL) on MSLT?

A

• Age
• Sleep deprivation
• Circadian rhythm
• Stimulants/sedatives
• Nap number (shortest latency in nap 3 or 4)

201
Q

What MSL values indicate severity of sleepiness?

A

<5 min = Severe
5–10 min = Moderate
10–15 min = Mild
>15 min = Normal

202
Q

What are common causes of SOREMPs besides narcolepsy?

A

• Depression
• Untreated OSA
• Shift work
• Delayed Sleep-Wake Phase Disorder
• REM-rebound after drug withdrawal

203
Q

What is the significance of documenting a SOREMP on the PSG prior to MSLT?

A

A SOREMP on PSG can substitute for one of the two required SOREMPs in diagnosing narcolepsy (especially NT1).

204
Q

What is the role of actigraphy before an MSLT?

A

Actigraphy documents sleep duration and regularity for 1–2 weeks prior and helps confirm adequate sleep before testing.

205
Q

Why should the MSLT not follow a split night or CPAP titration study?

A

Because sleep deprivation or altered sleep architecture may affect results, making the MSLT unreliable.

206
Q

What are key clinical documentation elements accompanying an MSLT?

A

• Patient perception of sleep
• Technologist observations
• 2-week sleep diary
• PSG results
• Urine drug screen
• Medication changes

207
Q

What substances can confound MSLT results if not discontinued?

A

• Stimulants
• Sedatives
• THC/marijuana
• SSRIs, SNRIs, TCAs (REM suppressants)

208
Q

What does the ICSD-3-TR say about diagnosing NT1 without PSG/MSLT?

A

If cataplexy is present and CSF hypocretin-1 is low, PSG/MSLT is not required to confirm NT1.

209
Q

What pattern of SOREMP onset is typical in NT1 vs idiopathic hypersomnia?

A

NT1 SOREMPs tend to arise from stage N1; in hypersomnia or insufficient sleep, SOREMPs often arise from stage N2.

210
Q

What is the typical distribution of SOREMPs across MSLT naps?

A

SOREMPs are most common in naps 1–3, particularly nap 2; least likely in nap 4.

211
Q

When is repeating an MSLT recommended?

A

When initial study has ambiguous results, inadequate conditions, or strong clinical suspicion persists despite negative results.

212
Q

What is the recommendation for number of naps in an MSLT?

A

Five naps are recommended, especially if MSL is 5–10 min or if there is only one SOREMP including PSG.

213
Q

What are the components of a standard MSLT report?

A

• Summary of history
• Medications and changes
• PSG findings
• Sleep diary and drug screen
• Results of each nap
• MSL and SOREMP count
• Diagnostic impression

214
Q

What are FDA-approved treatments for residual sleepiness in OSA?

A

Alerting agents such as modafinil, solriamfetol, and pitolisant (note: stimulants also used off-label).

215
Q

Why must patients be out of bed between MSLT naps?

A

To prevent inadvertent napping, which would invalidate the test results.

216
Q

What is the minimal total sleep time (TST) required on the PSG for MSLT to be valid?

A

360 minutes (6 hours).

217
Q

What finding during PSG suggests prior sleep restriction?

A

High sleep efficiency and high percentage of REM sleep.

218
Q

How is sustained sleep latency defined, and how does it help in diagnosis?

A

Time to three epochs of stage 1 or one epoch of any other stage; shorter sustained latency is more specific to narcolepsy.

219
Q

What is the significance of a high REM percentage and short REM latency on PSG before MSLT?

A

It may suggest prior sleep restriction or sleep deprivation, which can lead to false-positive MSLT results.

220
Q

Why is the MSLT not suitable for shift workers?

A

Because circadian misalignment may mimic narcolepsy, resulting in false-positive findings (short MSL, SOREMPs).

221
Q

In the diagnosis of NT2, what must be ruled out in addition to cataplexy?

A

Insufficient sleep, untreated OSA, medication effects, psychiatric conditions, and circadian rhythm disorders.

222
Q

How is cataplexy defined in NT1 diagnosis?

A

Brief, emotionally triggered loss of muscle tone with bilateral involvement, typically lasting under 2–3 minutes.

223
Q

What is the role of HLA-DQB1*06:02 in narcolepsy diagnosis?

A

It supports a diagnosis of NT1 when combined with cataplexy; nearly all NT1 patients are HLA-positive.

224
Q

What MSLT finding strongly supports NT1 when cataplexy is also present?

A

A SOREMP on PSG alone is sufficient to diagnose NT1 when cataplexy is present.

225
Q

What PSG/MSLT pattern is common in patients misdiagnosed with narcolepsy due to sleep deprivation?

A

High sleep efficiency, high REM %, short sleep latency, and multiple SOREMPs due to prior sleep debt.

226
Q

How does the MSLT help differentiate idiopathic hypersomnia from narcolepsy?

A

Idiopathic hypersomnia often lacks SOREMPs and shows longer, variable sleep latencies with fragmented sleep.

227
Q

What is the implication of REM sleep onset via stage N2 instead of N1 on MSLT?

A

It suggests the SOREMP is more likely due to insufficient sleep or hypersomnia than narcolepsy.

228
Q

What is the typical sleep stage progression into REM for narcolepsy patients?

A

REM sleep often occurs directly from wakefulness or stage N1 in narcolepsy, especially NT1.

229
Q

What adolescent-specific factors complicate MSLT interpretation?

A

Delayed sleep phase and higher likelihood of SOREMPs in early naps can mimic narcolepsy.

230
Q

What is the specificity of ≥3 SOREMPs on MSLT for narcolepsy?

A

Very high—indicates strong likelihood of narcolepsy, especially NT1.

231
Q

Why should actigraphy include weekends before MSLT?

A

To capture variability in sleep patterns and confirm consistency of adequate sleep duration.

232
Q

What is the role of audiovisual recording during MSLT?

A

Required during nap trials to confirm behavior and support scoring; recordings between naps are optional.

233
Q

In what situation is the MSLT result insufficient to diagnose NT2?

A

When SOREMPs and low MSL are present but insufficient sleep, medication, or psychiatric factors are not excluded.

234
Q

What is the purpose of biocalibration before each MSLT nap?

A

To ensure accurate signal quality for EEG, EOG, and EMG channels before lights out.

235
Q

What are the sensitivity and specificity ranges of the MSLT for diagnosing narcolepsy?

A

Sensitivity ranges from 78–92%; specificity from 71–95%, with better accuracy for NT1 than NT2.

236
Q

What are common causes of false-positive MSLT findings?

A

Sleep deprivation, shift work, recent withdrawal of REM-suppressing medications, or delayed sleep phase disorder.

237
Q

What are common causes of false-negative MSLT results?

A

Use of REM-suppressing medications, stimulants, anxiety, noise, or suboptimal test timing.

238
Q

In a clinical case, what features led to misdiagnosis of narcolepsy in a new parent?

A

High REM %, high sleep efficiency, short MSL, and 2 SOREMPs due to chronic sleep deprivation during postpartum care.

239
Q

What MSLT/PSG findings supported a diagnosis of narcolepsy despite treated OSA?

A

3 SOREMPs on MSLT with MSL of 2.5 minutes despite 60/60 days of CPAP use with good adherence and normal AHI.

240
Q

How should patients with persistent sleepiness despite treated OSA be evaluated?

A

Repeat PSG on CPAP followed by MSLT on CPAP to rule out comorbid narcolepsy.

241
Q

What finding during PSG suggests a risk for MSLT misinterpretation due to sleep restriction?

A

REM % >25% and sleep efficiency >95% may indicate prior sleep deprivation.

242
Q

What MSLT patterns are commonly misinterpreted in adolescents?

A

SOREMPs in naps 1–2 due to delayed sleep phase, not narcolepsy; interpretation should consider sleep schedule.

243
Q

How does age affect MSL and SOREMP prevalence?

A

MSL tends to increase with age; adolescents may show more SOREMPs early in the day due to circadian factors.

244
Q

What is the clinical significance of ≥3 SOREMPs on MSLT?

A

Very high specificity for narcolepsy, especially NT1.

245
Q

What minimum total sleep time is required on PSG for valid MSLT interpretation?

A

360 minutes (6 hours) of recorded sleep on PSG.

246
Q

When is a fifth MSLT nap recommended?

A

If average MSL after 4 naps is 5–10 minutes or if only one SOREMP (including PSG) has occurred.

247
Q

What is the recommended procedure for handling alerting medications before an MSLT?

A

Withdraw for ≥2 weeks; taper gradually to avoid rebound effects; consider half-life (e.g., fluoxetine may need 6 weeks).

248
Q

What is the threshold for increased accident risk based on MWT latency?

A

A mean sleep latency <19 minutes on MWT correlates with a fivefold increased accident risk.

249
Q

What factors must be ruled out before diagnosing NT2 with MSLT?

A

Insufficient sleep, psychiatric disorders, medications, circadian misalignment, and untreated OSA.

250
Q

How is a nocturnal SOREMP used in narcolepsy diagnosis?

A

Can replace one MSLT SOREMP in diagnosing NT1; highly specific when present.